45P FOR CASH.FULL TRIAL RESULTS TOO COME AS PER RNS.

4.89 MILL MKT CAP.12.7 MILL CASH +PLENTY MORE IN THE PORTFOLIO FOR FREE.WHEN WLL PI,S WAKE UP WHEN IT HITS THE LEADERBOARD.MENTAL

devlin, thanks but this is a massive disapointment surely? This has echos of Evolutec, who had several minor drugs running, but their lead product was found wanting....I guess the Market thinks that if their "best shot" is down, what hope for the others? It questions Management's ability....
NPH down again 25%-ish thursday - and frankly I can get a "slightly better" deal with Oxford Bio - who have slightly more cash and a strong tie with Sanoffi ( er, but in fairness the OXB-sp sank on a Trial "failure" =0h dear!) - but at 8p I guess OXB is marginly better for me, being full-list and one I've been with for many years ( yes I didn't see it coming, if you ask...but I don't think they believed it possible either, still hoping trial-data will show some value.
Have you attended any AGM's for Neuro....? I'd sure like to 2009.
EDIT.23Feb09-sp 6//9p (30% drop) as investment Co Aegon(?) drops below 3% -DYOR - this means they want OUT . . . . this needs to be significantly lower to be worth the risk......like 2//3p